The Future of Weight Loss: Next-Gen GLP-1 Drugs in Development
A look at the next generation of weight loss medications in the pipeline, including oral GLP-1s, triple agonists, and drugs targeting new pathways.
The Evolution Continues
The current generation of GLP-1 medications has already transformed the weight loss landscape, but the pharmaceutical pipeline promises even more effective, convenient, and accessible treatments in the coming years. Major pharmaceutical companies are racing to develop next-generation drugs that address the limitations of today's medications: the need for injections, gastrointestinal side effects, muscle mass loss, and the rebound weight gain that can occur after discontinuation.
Here is an in-depth look at what is coming and when we might expect these treatments to reach patients.
Oral GLP-1 Medications
Perhaps the most anticipated development is the advancement of oral GLP-1 formulations. While injectable GLP-1 medications are well-tolerated by most patients, a significant portion of the population is reluctant to self-inject. Oral options could dramatically expand the market and make these treatments accessible to millions more people.
Oral Semaglutide (High-Dose)
Novo Nordisk's oral semaglutide is already available at doses up to 14mg for diabetes under the brand name Rybelsus. Higher doses designed specifically for weight loss are in advanced clinical development. The OASIS 1 trial demonstrated that oral semaglutide at 50mg produced weight loss comparable to injectable semaglutide 2.4mg, with approximately 15-17% body weight reduction.
The challenge with oral semaglutide is bioavailability. Only a small fraction of the orally ingested drug reaches the bloodstream, which is why the oral dose is dramatically higher than the injectable dose. This requires taking the medication on an empty stomach with a small amount of water and waiting at least 30 minutes before eating, drinking, or taking other medications. For some patients, this routine is a significant inconvenience.
Amycretin (Oral)
Novo Nordisk's amycretin is a fascinating oral compound that combines GLP-1 and amylin receptor activity in a single molecule. Early clinical data has shown remarkable efficacy, with some trial participants losing over 13% of body weight in just 12 weeks. If these results hold in larger trials, amycretin could match or exceed injectable GLP-1 efficacy in a pill form, which would be a genuine breakthrough.
Triple Receptor Agonists
If dual agonists like tirzepatide represent the current frontier, triple agonists are the next one. These drugs activate three incretin-related receptors simultaneously: GLP-1, GIP, and glucagon receptors.
Retatrutide
Eli Lilly's retatrutide is the most advanced triple agonist in development. Phase 2 trial data was genuinely startling: at the highest dose tested, participants lost an average of 24.2% of body weight over 48 weeks. Some participants lost more than 30% of their body weight. If phase 3 results confirm these findings, retatrutide would set a new standard for pharmacological weight loss.
The glucagon receptor activation adds an important dimension. Glucagon promotes energy expenditure and fat oxidation, potentially helping address the metabolic adaptation that slows weight loss over time. This could mean more sustained weight loss and potentially better weight maintenance.
Other Triple Agonists
Several other companies are developing triple agonists, though none are as far along as retatrutide. The approach is validated by the mechanism and the clinical data, and we expect multiple entries in this category by 2028-2029.
Amylin-Based Therapies
Amylin is a pancreatic hormone that works alongside insulin to regulate appetite and glucose metabolism. Adding amylin receptor activation to GLP-1 therapy appears to enhance weight loss beyond what GLP-1 alone achieves.
CagriSema
Novo Nordisk's CagriSema combines semaglutide with cagrilintide, a long-acting amylin analog. The REDEFINE clinical program has shown that this combination produces greater weight loss than semaglutide alone, with phase 3 data demonstrating approximately 22-24% weight loss. CagriSema is expected to be among the first next-generation treatments to reach the market.
Importantly, the amylin component may help address one of semaglutide's limitations. Amylin appears to promote more favorable body composition changes, potentially preserving more lean mass during weight loss. If confirmed in larger studies, this would be a meaningful advantage over current single-mechanism approaches.
Muscle-Preserving Approaches
The loss of lean body mass during GLP-1 treatment has emerged as a significant concern, spurring research into combination therapies that could preserve or even build muscle while promoting fat loss.
GLP-1 Plus Myostatin Inhibitors
Myostatin is a protein that inhibits muscle growth. Blocking myostatin while simultaneously promoting fat loss through GLP-1 agonism could create a treatment that produces profound body composition improvements. Several companies are exploring this combination, though clinical data remains early-stage.
GLP-1 Plus ActRII Inhibitors
Activin receptor type II inhibitors promote muscle growth through a different mechanism. Early-stage trials combining these agents with GLP-1 medications have shown promising improvements in lean mass preservation. Expect more data in 2027-2028.
Novel Mechanisms
Beyond GLP-1-based approaches, entirely new mechanisms for weight management are emerging:
GDF-15 mimetics: Growth differentiation factor 15 (GDF-15) is a stress-response hormone that profoundly suppresses appetite through brainstem receptors distinct from those targeted by GLP-1. GDF-15-based drugs could work alongside or as alternatives to GLP-1 medications.
Leptin sensitizers: Leptin resistance is a hallmark of obesity. Drugs that restore leptin sensitivity could address one of the fundamental hormonal imbalances driving weight gain and making weight maintenance difficult.
Brown fat activators: Compounds that increase brown adipose tissue activity could boost energy expenditure without exercise, offering another tool in the weight management arsenal.
Timeline and Access
Based on current clinical development timelines, here is when we expect key next-generation treatments to become available:
- 2026-2027: High-dose oral semaglutide for weight loss, CagriSema
- 2027-2028: Retatrutide, oral amycretin
- 2028-2030: Muscle-preserving combinations, novel mechanism drugs
Pricing and insurance coverage will be critical factors determining real-world access. As the market becomes more competitive, there is hope that prices will moderate, particularly as current GLP-1 patents begin to expire and biosimilar development accelerates.
What This Means for Current Patients
If you are currently on a GLP-1 medication or considering starting one, the advancing pipeline is encouraging. It means that even if your current medication produces suboptimal results, more effective options are likely on the horizon. However, waiting for a future medication rather than addressing weight-related health risks now is generally not advisable.
The best strategy is to begin treatment with currently available medications while staying informed about developments. Resources like GLP-1 Watchdog track the clinical pipeline and provide updates on new approvals, helping patients and providers make informed decisions about when newer options might be worth considering.
The weight loss medication landscape is evolving faster than at any point in medical history. For the millions of people struggling with obesity, the future holds unprecedented promise for effective, accessible, and well-tolerated treatments that could fundamentally change their health trajectory.
About This Review
This article was researched and written by the Health Products In Review editorial team. We maintain strict editorial independence and do not accept payment from companies whose products we review. Last updated: February 20, 2026.